Journal Article Summary
The article investigates allergic reactions that occur after the first dose of mRNA COVID-19 vaccines, specifically focusing on the role of skin testing for excipients like polyethylene glycol (PEG) and polysorbate 80. This topic is significant because the Centers for Disease Control and Prevention (CDC) advises against administering a second dose of the vaccine to individuals who have experienced severe or immediate allergic reactions to the first dose. Understanding the relationship between these allergic reactions and the excipients in the vaccines can help guide vaccination strategies and improve patient safety.
The study involved 80 patients who reported allergic reactions after their first dose of an mRNA COVID-19 vaccine. These patients underwent skin testing to assess their sensitivity to PEG and polysorbate 80. The results showed that 18% of the patients had positive skin tests for these excipients, but the majority (88%) were able to receive the second dose of the vaccine without significant issues. Most of those who experienced reactions had mild symptoms that were manageable with antihistamines, while only two patients required epinephrine for their reactions.
Limitations of the study include its focus on a specific patient population, which may not represent the broader community, and the reliance on self-reported symptoms, which can introduce bias. Patients should consult with healthcare professionals about their allergic reactions and the potential need for skin testing before receiving a second dose of the vaccine. It is essential to discuss individual risk factors and vaccination options, including the possibility of using alternative vaccines like the Janssen vaccine, especially for those with concerns about PEG allergies.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Wolfson Anna R., Robinson Lacey B., Li Lily, McMahon Aubree E., Cogan Amelia S., Fu Xiaoqing, Wickner Paige, Samarakoon Upeka, et al.. First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing. The Journal of Allergy and Clinical Immunology. in Practice 2021. DOI: 10.1016/j.jaip.2021.06.010. PMID: 34166844. PMCID: PMC8217699.
Featured Pill Pals Product
Loratadine 10 mg --- 300 Count Bottle --- Generic For Claritin --- Major / Rugby --- Over The Counter
Loratadine 10 mg — 300 Count Bottle — Generic For Claritin — Major / Rugby — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
